# GLP-1 Weight-Loss Search Interest by Gender

> Women search for GLP-1 weight-loss treatments 2.5× more than men — a gap that held firm in both 2025 and 2026

**Period:** August 2025 vs. August 2026  
**Market:** DE  
**Data status:** final  
**Data as of:** 2026-08-31T16:32:29.834559+00:00  
**Sample size:** n = 15,288  
**Effective sample size:** 7,357  
**Source:** [https://www.datapods.app/en/insights/digital/search-queries/glp1-search-interest-gender-germany-2026](https://www.datapods.app/en/insights/digital/search-queries/glp1-search-interest-gender-germany-2026)

## Segments

- **Years:** 2025–2026
- **Platform:** search
- **Gender:** male, female

## Summary

Women's GLP-1 search-interest rate runs roughly 2.5 times higher than men's in Germany — a structural gap that persisted unchanged from August 2025 to August 2026, and predates the imminent oral Wegovy launch.

## A gender skew mirrored in clinical uptake

The pattern is consistent with real-world prescription data. Research on oral semaglutide uptake in other EU markets found the oral form was more frequently used by younger females — aligning with the demographic profile of tablet-specific searchers in Germany, 68% of whom were female. Ahead of the 1 September 2026 Wegovy pill launch in German pharmacies, this persistent gender gap signals that women will likely be the primary adopters of the new oral format — both because they are the dominant research audience now, and because needle aversion may be more prevalent as a stated barrier. The age-group breakdown behind these aggregate rates is explored in [GLP-1 search interest by age group](slug:glp1-search-interest-by-age-germany-2026).

## Chart

Grouped bar chart showing weighted GLP-1 weight-loss search-interest rates for men and women in Germany for August 2025 and August 2026. Error bars indicate 95% confidence intervals. Women's rates are approximately 2.5 times higher than men's in both years.

## Methodology

The search-interest rate for each gender is the share of male and female German adult online searchers active in August 2025 or August 2026 who queried GLP-1 weight-loss terms (Wegovy, Ozempic, Saxenda, Mounjaro, semaglutide, tirzepatide, and related terms). Rates are calibrated to the German adult online population (18+) and weighted to reflect demographic composition. The gender comparison is the robust finding; absolute percentages are panel-internal rates.

## Citation

Datapods (2026-08-31). *GLP-1 Weight-Loss Search Interest by Gender*. Datapods Insights. https://www.datapods.app/en/insights/digital/search-queries/glp1-search-interest-gender-germany-2026

## About Datapods

Datapods is a behavioral consumer-data platform. The Insights library publishes free, citable statistics derived from a panel of 25,000+ opted-in participants in Germany: observed real behavior (transactions, browsing, media), not surveys. All data is processed within the EU and is GDPR-compliant.

For brand-specific cuts, competitor benchmarks, and granular audience filters across 12,000+ tracked brands, see [https://www.datapods.app/en](https://www.datapods.app/en).